Circio Holding ASA — Director's Dealing 2026

May 29, 2026

Circio Holding ASA Exercise of Warrants by primary insiders

Circio Holding ASA Exercise of Warrants by primary insiders

Oslo, 29 May 2026: Reference is made to the stock exchange announcement

published by Circio Holding ASA (the "Company") on 26 May 2026 regarding

commencement of the exercise period for warrants from 26 May to 9 June 2026

(the "Exercise Period").

Certain primary insiders and close associates have on the dates stated below,

exercised warrants for the allocation of shares:

* Robert Burns, deputy member of the board of directors of the Company, has on

27 May 2026 exercised a total of 5,000 warrants, for the allocation of 5,000

shares in the Company at a price of NOK 8.2508 per share. Following the

delivery of shares from the exercising warrants, Burns will hold 105,000

shares in the Company.

* Digman AS, a company owned by Erik Digman Wiklund, CEO of the Company, has

on 28 May 2026 exercised a total of 42,420 warrants, for the allocation of

42,420 shares in the Company at a price of NOK 8.2508 per share. Following

the delivery of shares from the exercising warrants, Wiklund will hold

770,553 shares in the Company, including shares held through Digman AS.

A total of 67,680,945 warrants were issued on ISIN NO0013711523 in connection

with the rights issue and related private placement completed in February 2026

(Nw.: frittstående tegningsretter) (the "Warrants"). Each Warrant gives the

holder the right to subscribe for one (1) new share in Circio at the exercise

price of NOK 8.2508 per share, during the Exercise Period.

Please see the attached notifications of trade for information regarding the

exercise of Warrants by primary insiders of the Company.

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683 34 3811

Email: lubor.gaal@circio.com

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 50-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.